News Quantified

ASND – ascendis pharma a/s - american depositary shares (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia

The Interleukin-2 Market is Set to Reach USD 4 Billion by 2034, Driven by IL-2 Targeting Fusion Proteins, Monoclonal antibodies, and Gene Therapies Across Immunology, Dermatology, Neurodegenerative Disorders, and Oncology | DelveInsight

The Interleukin-2 Market is Set to Reach USD 4 Billion by 2034, Driven by IL-2 Targeting Fusion Proteins, Monoclonal antibodies, and Gene Therapies Across Immunology, Dermatology, Neurodegenerative Disorders, and Oncology | DelveInsight

Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at JPMorgan Chase & Co. from $168.00 to $200.00. They now have an "overweight" rating on the stock.

OMass Therapeutics appoints Birgitte Volck as Non-Executive Director

13.0%

BEAT

13.0%

BEAT

13.0%

BEAT

13.0%

BEAT

Cantor Fitzgerald

Evercore ISI Group

Form 6-K Ascendis Pharma A/S For: Mar 31

Form 6-K Ascendis Pharma A/S For: Mar 28

Form 6-K Ascendis Pharma A/S For: Mar 20

Form 6-K Ascendis Pharma A/S For: Mar 12

Form 144 Ascendis Pharma A/S Filed by: JENSEN MICHAEL WOLFF

Top News Gainers

4/20 Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Oppenheimer Holdings Inc. from $199.00 to $219.00. They now have an "outperform" rating on the stock. 9.1%

11/18 Ascendis Pharma A/S Reports Third Quarter 2019 Financial Results 6.3%

6/3 Ascendis Pharma A/S (NASDAQ: ASND) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $223.00 price target on the stock, up previously from $219.00. 6.0%

6/14 Form 6-K Ascendis Pharma A/S For: Jun 14 5.5%

11/22 Ascendis Pharma A/S (NASDAQ: ASND) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.3%

12/17 Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Morgan Stanley from $134.00 to $140.00. They now have an "overweight" rating on the stock. 4.6%

12/25 Ascendis Pharma A/S (NASDAQ: ASND) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 4.1%

10/10 Form 6-K Ascendis Pharma A/S For: Oct 10 3.8%

11/20 Edited Transcript of ASND earnings conference call or presentation 18-Nov-19 9:30pm GMT [Yahoo! Finance News] 3.7%

4/14 Ascendis Pharma A/S (NASDAQ: ASND) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 3.6%

Top News Decliners

6/26 Form 6-K Ascendis Pharma A/S For: Jun 26 -9.8%

9/26 Ascendis Pharma A/S Announces Upcoming Investor Presentation in October -7.5%

4/20 Form 6-K Ascendis Pharma A/S For: Apr 20 -5.8%

5/30 Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] -5.4%

8/29 Ascendis Pharma A/S (ASND) Q2 2019 Earnings Call Transcript [The Motley Fool] -5.2%

3/31 Sofinnova Investments Strengthens Executive Team with Promotions of Maha Katabi, PhD, CFA and Sarah Bhagat, PhD -5.0%

11/15 Form 6-K Ascendis Pharma A/S For: Nov 15 -4.2%

7/1 Form 6-K Ascendis Pharma A/S For: Jul 01 -3.9%

4/2 Ascendis Pharma A/S (ASND) Q4 2019 Earnings Call Transcript [The Motley Fool] -3.6%

6/10 Form SC 13G/A Ascendis Pharma A/S Filed by: PRICE T ROWE ASSOCIATES INC /MD/ -3.5%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day